News
AMLX
3.870
+1.57%
0.060
Weekly Report: what happened at AMLX last week (0317-0321)?
Weekly Report · 4d ago
Weekly Report: what happened at AMLX last week (0310-0314)?
Weekly Report · 03/17 09:23
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga · 03/12 12:36
Weekly Report: what happened at AMLX last week (0303-0307)?
Weekly Report · 03/10 09:23
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
NASDAQ · 03/07 15:58
Cautious Hold Rating for Amylyx Pharmaceuticals Amid Key Clinical Updates and Stable Financial Position
TipRanks · 03/07 08:02
Amylyx Pharmaceuticals Co-CEOs Cash In on Stock Sales!
TipRanks · 03/06 02:02
Amylyx Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones · 03/05 13:19
HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $12 Price Target
Benzinga · 03/05 13:09
Buy Rating for Amylyx Pharmaceuticals: Avexitide’s Potential in Post-Bariatric Surgery Market
TipRanks · 03/05 13:05
Amylyx Pharmaceuticals Faces Challenges in Acquisition Strategy Amid RELYVRIO Discontinuation
TipRanks · 03/05 06:02
Amylyx Pharmaceuticals Reports 2024 Financial Results
TipRanks · 03/05 04:15
Amylyx Pharmaceuticals’ Earnings Call Highlights Clinical Progress
TipRanks · 03/05 00:22
Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 03/04 15:18
BUZZ-Amylyx Pharmaceuticals falls on quarterly loss
Reuters · 03/04 14:37
Amylyx files $300M mixed securities shelf
TipRanks · 03/04 12:35
AMYLYX PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $300 MLN – SEC FILING
Reuters · 03/04 12:31
Amylyx Pharma Q4 EPS $(0.55) Misses $(0.52) Estimate
Benzinga · 03/04 11:10
Amylyx reports Q4 EPS (55c) vs. 7c last year
TipRanks · 03/04 11:05
Amylyx Pharmaceuticals GAAP EPS of -$0.55 misses by $0.03, revenue of -$0.67M
Seeking Alpha · 03/04 11:03
More
Webull provides a variety of real-time AMLX stock news. You can receive the latest news about Amylyx Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About AMLX
More
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.